Traduction de «al development » (Français → Néerlandais) :

Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.
This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.

Pfizer News : R&D et Business Development
Pfizer News : O&O en Business Development

Home > Médias > Communiqués de presse > R&D et Business Development
Home > Media > Persberichten > O&O en Business Development

R&D et Business Development| Pfizer Belgium
O&O en Business Development| Pfizer Belgium

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.
FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties.
DISCLOSURE NOTICE: The information contained in this release is as of September 1, 2010. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Marie-Claire Hamès, régente en économie sociale et familiale, enseignante et membre du Comité Consultatif de l’AFSCA pour la Communauté germanophone Siska Pottie, conseillère ‘politique alimentaire’ chez FEVIA Myriam Lambillon, coordinatrice de l’Union des Agricultrices Wallonnes Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’ au CRIOC
Marie-Claire Hamès, regentes in sociale en huishoudelijke economie, leerkracht, lid van het Raadgevend Comité van het FAVV voor de Duitstalige Gemeenschap Siska Pottie, adviseur voedingsbeleid, FEVIA Myriam Lambillon, coördinatrice van de ’ ‘Union des Agricultrices Wallonnes’ Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’, OIVO

Marie-Claire Hamès, régente en économie sociale et familiale, enseignante et membre du comité consultatif de l’AFSCA pour la Communauté germanophone Siska Pottie, Conseillère «politique alimentaire», FEVIA Myriam Lambillon, Coordinatrice de l’Union des Agricultrices Wallonnes Ingrid Vanhaevre, Directeur ‘Strategic and Policy Development’, CRIOC
Marie-Claire Hamès, regentes in sociale en huishoudelijke economie, leerkracht, lid van het Raadgevend Comité van het FAVV voor de Duitse Gemeenschap Siska Pottie, adviseur voedingsbeleid, FEVIA Myriam Lambillon, coördinatrice van de ’ ‘Union des Agricultrices Wallonnes’ Ingrid Vanhaevre, directeur ‘Strategic and Policy Development’, OIVO

[12] Pastoret P.-P. et al. Development and deliberate release of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.
[12] Pastoret P.-P. et al. Development and deliberate relaese of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.